- Home
- MSB vs MYGN Comparison
MSB vs MYGN Comparison
Compare MSB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | MYGN |
|---|---|---|
| Founded | 1961 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 481.6M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MSB | MYGN |
|---|---|---|
| Price | $31.89 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 43.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 391.29 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | $98,595,651.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | $37.67 | ★ N/A |
| Revenue Growth | ★ 331.26 | 2.33 |
| 52 Week Low | $22.55 | $3.76 |
| 52 Week High | $42.38 | $10.32 |
Technical Indicators
Market Signals| Indicator | MSB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 41.35 |
| Support Level | $28.62 | $3.93 |
| Resistance Level | $32.94 | $5.63 |
| Average True Range (ATR) | 2.11 | 0.42 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 54.55 | 21.43 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.